Loading
Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant.
Aditya Bardia was principal investigator of ASCENT, which showed sacituzumab govitecan nearly doubles survival in pretreated metastatic TNBC, and of EMERALD, which won elacestrant the first oral SERD approval for ESR1-mutant disease. He is a lead investigator on the TROPION-Breast programme and ctDNA-guided studies. His work has defined the TROP2 ADC class in breast cancer.
Chinese patients in the trial saw the same pattern as the global population: a clear progression-free survival gain, no proven survival gain, and a different rather than heavier side-effect burden, with mouth and eye toxicity in nearly half. It supports use of datopotamab deruxtecan in this setting in China but does not resolve the global trial's missing survival benefit.
For unresectable or metastatic hormone-receptor-positive, HER2-negative breast cancer after endocrine-based therapy and chemotherapy for advanced disease, Dato-DXd is an FDA-approved option. TROPION-Breast01 showed longer progression-free survival and fewer severe treatment-related adverse events than chemotherapy; the final overall survival analysis did not show a statistically significant improvement. Approval in this setting does not establish a survival advantage or apply to postoperative early-stage disease.
TROP2 IHC does not gate sacituzumab govitecan: the label requires no test, and the corpus records TROP2 as an expression readout without a threshold.
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares the tags breast, trialist.
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags breast, adc.
Shares UCLA Jonsson Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tags breast, trialist.
Shares HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares Antibody-drug conjugate (ADC) and the tags breast, adc.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/